{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:02:58Z","timestamp":1781247778095,"version":"3.54.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK29867"],"award-info":[{"award-number":["DK29867"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK27619"],"award-info":[{"award-number":["DK27619"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0158703","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T17:27:16Z","timestamp":1468258036000},"page":"e0158703","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exenatide Treatment Alone Improves \u03b2-Cell Function in a Canine Model of Pre-Diabetes"],"prefix":"10.1371","volume":"11","author":[{"given":"Viorica","family":"Ionut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orison O.","family":"Woolcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik J.","family":"Mkrtchyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Stefanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morvarid","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini S.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana V. B.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane L.","family":"Broussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn M.","family":"Kolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Asare-Bediako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2337\/db07-9903","article-title":"Orchestration of glucose homeostasis: from a small acorn to the California oak","volume":"56","author":"RN Bergman","year":"2007","journal-title":"Diabetes"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"L Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2042018815580257","article-title":"Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance","volume":"6","author":"SH Tella","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care","volume":"30","author":"DM Nathan","year":"2007","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"2. Classification and Diagnosis of Diabetes","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/M14-2221","article-title":"Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force","volume":"162","author":"S Selph","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.mcna.2010.11.003","article-title":"Epidemiology of prediabetes","volume":"95","author":"S Colagiuri","year":"2011","journal-title":"Med Clin North Am"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"J Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4158\/EP11194.OR","article-title":"Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta-cell dysfunction","volume":"18","author":"J Armato","year":"2012","journal-title":"Endocr Pract"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1475-2840-11-64","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial","volume":"11","author":"AS Kelly","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2337\/dc09-1957","article-title":"Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults","volume":"33","author":"A Karve","year":"2010","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"E1311","DOI":"10.1152\/ajpendo.90972.2008","article-title":"Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs","volume":"296","author":"JM Richey","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1152\/ajpendo.00466.2009","article-title":"Novel Canine Models of Obese Pre-Diabetes and of Mild Type 2 Diabetes","volume":"298","author":"V Ionut","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"E644","DOI":"10.1152\/ajpendo.00244.2014","article-title":"Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia","volume":"307","author":"V Ionut","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e18134","DOI":"10.1371\/journal.pone.0018134","article-title":"Consistency of the Disposition Index in the Face of Diet Induced Insulin Resistance: Potential Role of FFA","volume":"6","author":"D Stefanovski","year":"2011","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/oby.20906","article-title":"Increase in visceral fat per se does not induce insulin resistance in the canine model","volume":"23","author":"AVB Castro","year":"2015","journal-title":"Obesity"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/oby.20625","article-title":"Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog","volume":"22","author":"M Ader","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e0123558","DOI":"10.1371\/journal.pone.0123558","article-title":"High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets","volume":"10","author":"OO Woolcott","year":"2015","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MPA.0b013e318221fd0e","article-title":"Simplified method to isolate highly pure canine pancreatic islets","volume":"41","author":"OO Woolcott","year":"2012","journal-title":"Pancreas"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ceca.2006.02.003","article-title":"Arachidonic acid is a physiological activator of the ryanodine receptor in pancreatic beta-cells","volume":"39","author":"OO Woolcott","year":"2006","journal-title":"Cell Calcium"},{"key":"ref21","first-page":"387","author":"LC Hamilton","year":"2008"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1139\/h2012-068","article-title":"Alterations in energy balance following exenatide administration","volume":"37","author":"DP Bradley","year":"2012","journal-title":"Appl Physiol Nutr Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"B Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"DM Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"JJ Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/dc09-1521","article-title":"Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin","volume":"33","author":"RA DeFronzo","year":"2010","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.24.1.89","article-title":"Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development","volume":"24","author":"C Weyer","year":"2001","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-200666010-00005","article-title":"Pioglitazone: a review of its use in type 2 diabetes mellitus","volume":"66","author":"J Waugh","year":"2006","journal-title":"Drugs"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cen.12199","article-title":"The effect of chronic twice daily exenatide treatment on beta-cell function in new onset type 2 diabetes","volume":"80","author":"A Gastaldelli","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2337\/db08-0875","article-title":"Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver","volume":"58","author":"D Zheng","year":"2009","journal-title":"Diabetes"},{"key":"ref31","first-page":"1410","article-title":"Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans","volume":"45","author":"A Vella","year":"2002","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"BR Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1530\/JOE-13-0426","article-title":"Mechanism of the beneficial and protective effects of exenatide in diabetic rats","volume":"220","author":"M Lotfy","year":"2014","journal-title":"J Endocrinol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.peptides.2011.03.018","article-title":"Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes","volume":"32","author":"L Wang","year":"2011","journal-title":"Peptides"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0006-2952(01)00924-8","article-title":"Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1","volume":"63","author":"I Idris","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro","volume":"50","author":"DG Parkes","year":"2001","journal-title":"Metabolism"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9\u201339)-amide an antagonist at the glucagon-like peptide 1-(7\u201336)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"R Goke","year":"1993","journal-title":"J Biol Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1463-1326.2007.00838.x","article-title":"Effects of exendin-4 on islets from type 2 diabetes patients","volume":"10","author":"R Lupi","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00125-012-2802-z","article-title":"The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation","volume":"56","author":"YJ Park","year":"2013","journal-title":"Diabetologia"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3727\/096368911X576027","article-title":"Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets","volume":"21","author":"SR Cechin","year":"2012","journal-title":"Cell Transplantation"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"W Kim","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"ref42","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.2337\/dc11-s230","article-title":"Incretin effects on beta-cell function, replication, and mass: the human perspective","volume":"34","author":"AJ Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.2337\/db13-0822","article-title":"Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls","volume":"62","author":"DJ Drucker","year":"2013","journal-title":"Diabetes"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4161\/isl.3.5.15938","article-title":"Detailed protocol for evaluation of dynamic perifusion of human islets to assess beta-cell function","volume":"3","author":"K Bentsi-Barnes","year":"2011","journal-title":"Islets"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11892-009-0032-7","article-title":"Pathophysiology of prediabetes","volume":"9","author":"MA Abdul-Ghani","year":"2009","journal-title":"Curr Diab Rep"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc16-S005","article-title":"Classification and Diagnosis of Diabetes","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI110398","article-title":"Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose","volume":"68","author":"RN Bergman","year":"1981","journal-title":"J Clin Invest"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1258\/la.2010.010090","article-title":"Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models","volume":"45","author":"MC Deeds","year":"2011","journal-title":"Lab Anim"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0158703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T23:31:52Z","timestamp":1656804712000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0158703"}},"subtitle":[],"editor":[{"given":"Marta Letizia","family":"Hribal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0158703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}